^
Association details:
| Biomarker: | EGFR expression + ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR + and ALK + Positive Non-small-cell Lung Cancer Treated in the Real-World
Published date:
02/04/2021
Excerpt:
We assessed the proportion of patients with advanced epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) who receive tyrosine kinase inhibitors (TKIs) in the real-world, predictors of TKI use...TKI use was associated with longer OS in a multivariate extended Cox model and in the landmark analysis (adjusted hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.33; 0.99; P = .048; adjusted HR, 0.55; 95% CI, 0.30; 1.00; P = .050).
DOI:
10.1016/j.cllc.2021.01.019
